Cargando…

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells

Chronic myeloid leukemia (CML) is a hematologic disorder characterized by the oncogene BCR-ABL1, which encodes an oncoprotein with tyrosine kinase activity. Imatinib, a BCR-ABL1 tyrosine kinase inhibitor, performs exceptionally well with minimal toxicity in CML chemotherapy. According to clinical tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prado-Carrillo, Omar, Arenas-Ramírez, Abner, Llaguno-Munive, Monserrat, Jurado, Rafael, Pérez-Rojas, Jazmin, Cervera-Ceballos, Eduardo, Garcia-Lopez, Patricia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317189/ https://www.ncbi.nlm.nih.gov/pubmed/35887063 http://dx.doi.org/10.3390/ijms23147715

Ejemplares similares

Tuberostemonine reverses multidrug resistance in chronic myelogenous leukemia cells K562/ADR
por: Wang, Yu Jia, et al.
Publicado: (2017)

The Therapeutic Potential of Chemo/Thermotherapy with Magnetoliposomes for Cancer Treatment
por: Toro-Córdova, Alfonso, et al.
Publicado: (2022)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

Mifepristone Repurposing in Treatment of High-Grade Gliomas
por: Llaguno-Munive, Monserrat, et al.
Publicado: (2021)

Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments
por: Xu, Lianrong, et al.
Publicado: (2019)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2014)

Mifepristone improves chemo-radiation response in glioblastoma xenografts
por: Llaguno-Munive, Monserrat, et al.
Publicado: (2013)

Pharmacokinetics and Anti-Tumor Efficacy of PEGylated Liposomes Co-Loaded with Cisplatin and Mifepristone
por: Ocaña-Arakachi, Karen, et al.
Publicado: (2023)

Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity
por: Long, Mark D., et al.
Publicado: (2015)

Lapatinib Induces Autophagy, Apoptosis and Megakaryocytic Differentiation in Chronic Myelogenous Leukemia K562 Cells
por: Huang, Huey-Lan, et al.
Publicado: (2011)

Prodigiosin induced the caspase-dependent apoptosis in human chronic myelogenous leukemia K562 cell
por: Niakani, Maryam, et al.
Publicado: (2020)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

Calcitonin receptor gene expression in K562 chronic myelogenous leukemic cells
por: Mould, Richard, et al.
Publicado: (2003)

Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia
por: Schaefer, Bianca, et al.
Publicado: (2017)

Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX
por: Wu, Jingjing, et al.
Publicado: (2019)

Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells
por: Shi, Dan, et al.
Publicado: (2016)

Curcumin and Curcumin-Loaded Nanogel Induce Apoptosis Activity in K562 Chronic Myelogenous Leukemia Cells
por: Khatamsaz, Sepideh, et al.
Publicado: (2018)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
por: Oh, Hyun Jin, et al.
Publicado: (2013)

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells
por: Peng, Xing-Xiang, et al.
Publicado: (2012)

Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells
por: Regev, Ofer, et al.
Publicado: (2020)

Polyamine analog TBP inhibits proliferation of human K562 chronic myelogenous leukemia cells by induced apoptosis
por: WANG, QING, et al.
Publicado: (2015)

Inhibition of abl Oncogene Tyrosine Kinase Induces Erythroid Differentiation of Human Myelogenous Leukemia K562 Cells
por: Honma, Yoshio, et al.
Publicado: (1990)

Human Platelets Effectively Kill K‐562 Cells, a Chronic Myelogenic Leukemia Cell Line, in vitro
por: Sagawa, Terutaka, et al.
Publicado: (1990)

Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis
por: Wang, Wenjing, et al.
Publicado: (2019)

Ketoconazole Allergy
por: Ensina, Luis Felipe, et al.
Publicado: (2009)

Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence
por: Drullion, C, et al.
Publicado: (2012)

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2011)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
por: Martinelli, Giovanni, et al.
Publicado: (2009)

HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation
por: Kim, Soo Jung, et al.
Publicado: (2014)

Corrigendum to “Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis”
por: Wang, Wenjing, et al.
Publicado: (2021)

Near-Infrared Fluorescence Imaging in Preclinical Models of Glioblastoma
por: Llaguno-Munive, Monserrat, et al.
Publicado: (2023)

Cytotoxic effects of the compound cis-tetraammine(oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cells
por: Pereira, Flávia de Castro, et al.
Publicado: (2014)

Effect of bovine dialyzable leukocyte extract on induction of cell differentiation and death in K562 human chronic myelogenous leukemia cells
por: Sierra-Rivera, Crystel A., et al.
Publicado: (2016)

Wogonin reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12-CXCR4/7 axis in bone marrow microenvironment
por: Cao, Hanbo, et al.
Publicado: (2020)

Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous Leukemia
por: Jelinek, Jaroslav, et al.
Publicado: (2011)

Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
por: Obr, Adam, et al.
Publicado: (2014)

Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells
por: De Rosa, Viviana, et al.
Publicado: (2019)

NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia
por: Wang, Xiao, et al.
Publicado: (2023)

Correction: Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tbtddaqhjkmg78mm1h0823o233